Cargando…

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

BACKGROUND: Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC). METHODS: We examined the activity of sunitinib on a continuous daily dosing (CDD) schedule in an op...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novello, S, Scagliotti, G V, Rosell, R, Socinski, M A, Brahmer, J, Atkins, J, Pallares, C, Burgess, R, Tye, L, Selaru, P, Wang, E, Chao, R, Govindan, R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778527/ https://www.ncbi.nlm.nih.gov/pubmed/19826424 http://dx.doi.org/10.1038/sj.bjc.6605346

Ejemplares similares

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
por: Novello, S, et al.
Publicado: (2010)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results
por: Eisen, T, et al.
Publicado: (2015)

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
por: Yi, J H, et al.
Publicado: (2012)

Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial
por: Cella, David, et al.
Publicado: (2014)

Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
por: Michaelson, M D, et al.
Publicado: (2013)

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
por: Robert, Francisco, et al.
Publicado: (2009)

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
por: Rovithi, Maria, et al.
Publicado: (2016)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J J, et al.
Publicado: (2018)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J. J., et al.
Publicado: (2017)

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
por: Lankheet, N A G, et al.
Publicado: (2014)

Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer
por: Scagliotti, Giorgio, et al.
Publicado: (2010)

A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer
por: Chow, L. Q. M., et al.
Publicado: (2011)

The complexity of sunitinib dosing in renal cell cancer patients
por: Desar, Ingrid M.E., et al.
Publicado: (2012)

A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma
por: Lewin, J, et al.
Publicado: (2014)

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
por: Wang, X, et al.
Publicado: (2013)

Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients
por: Lin, Hsin, et al.
Publicado: (2016)

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
por: Nguyen, James, et al.
Publicado: (2023)

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer
por: Chen, H, et al.
Publicado: (2014)

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours
por: Ang, Yvonne L. E., et al.
Publicado: (2020)

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies
por: Harvey, R D, et al.
Publicado: (2013)

The yin yang of sunitinib: One drug, two doses, and multiple outcomes
por: Elgendy, Mohamed
Publicado: (2017)

Daily Dosing for Bedaquiline in Patients with Tuberculosis
por: Salinger, David H., et al.
Publicado: (2019)

Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010)

Phase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases
por: Tong, Charles C. L., et al.
Publicado: (2012)

Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185
por: Buckstein, R., et al.
Publicado: (2007)

Phase II study of sunitinib as second-line treatment for advanced gastric cancer
por: Bang, Yung-Jue, et al.
Publicado: (2010)

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
por: Barrios, Carlos H., et al.
Publicado: (2010)

Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis
por: Kang, Hee Jung, et al.
Publicado: (2020)

Sunitinib induced nephrotic syndrome and thrombotic microangiopathy
por: Jha, P. K., et al.
Publicado: (2013)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers
por: Wu, C, et al.
Publicado: (2015)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Sunitinib and other targeted therapies for renal cell carcinoma
por: Powles, T, et al.
Publicado: (2011)

Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction
por: Kleibeuker, Esther A, et al.
Publicado: (2015)

FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma
por: Horn, Kevin P., et al.
Publicado: (2015)

Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats
por: Hashemian, Mohammad Nasser, et al.
Publicado: (2017)

Contrasting effects of sunitinib within in vivo models of metastasis
por: Welti, Jonathan C., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_p52hcnheamvl3144bqoa08rrni